Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|October 1, 2006

Applied Clinical Trials

  • Applied Clinical Trials-10-01-2006
  • Volume 0
  • Issue 0

eShowcase: eCTDXPress Aspire

Regulatory submission solution addresses the needs of smaller biotech and pharma companies

Regulatory submission solution addresses the needs of smaller biotech and pharma companies

eCTDXPress Aspire

Image Solutions, Inc. (Whippany, NJ) recently released eCTDXPress Aspire, its Web-based eSubmissions software package. The electronic regulatory submissions package is targeted toward growing biotech and small pharmaceutical companies. The software enables smaller organizations the ability to create and manage submissions in-house to ensure they are correctly implemented and validated.

eCTDXPress Aspire is fully scalable, a convenient feature for companies anticipating future growth. Other features include life cycle management capability, on-site maintenance and support from Image Solutions, and the availability of ISI consultants for regulatory operations submission help—a good way for employees to gain knowledge and experience in building eCTDs in-house. The eCTDXPress Aspire package includes eCTDXPress Compiler, which helps ensure submissions are built to agency specifications, and eCTDXPress Manager, a central eCTD repository.

Image Solutions, Inc., (973) 560-0404, www.imagesolutions.com

Articles in this issue

about 20 years ago

Assessing Safety in Clinical Trials

about 20 years ago

eShowcase: LabPas CT 2.5

about 20 years ago

Informed Consent Considerations

about 20 years ago

eShowcase: GlobalView EventNet

about 20 years ago

Broad Introduction to CTs

about 20 years ago

CDISC Standards Energize EDC

Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.